BIAF logo

bioAffinity Technologies, Inc. Stock Price

NasdaqCM:BIAF Community·US$9.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

BIAF Share Price Performance

US$2.17
-37.73 (-94.56%)
US$2.17
-37.73 (-94.56%)
Price US$2.17

BIAF Community Narratives

There are no narratives available yet.

Snowflake Analysis

Moderate risk and fair value.

5 Risks
1 Reward

bioAffinity Technologies, Inc. Key Details

US$7.7m

Revenue

US$5.4m

Cost of Revenue

US$2.3m

Gross Profit

US$14.0m

Other Expenses

-US$11.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-2.60
29.87%
-152.18%
-3.7%
View Full Analysis

About BIAF

Founded
2014
Employees
57
CEO
Maria Zannes
WebsiteView website
www.bioaffinitytech.com

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Recent BIAF News & Updates

Recent updates

No updates